GlassScriptPhysician profile
Emily W Matlin
NPI 1558322974
$62,056.28
in general payments reported to CMS, 2019-2025
38 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $21K · 2021: $2,339 · 2022: $2,069 · 2023: $1,808 · 2024: $1,065 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,088.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35,855.95 | 2019-2025 | Kisunla, Emgality |
| Allergan, INC. | $9,619.37 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $6,650.47 | 2019-2024 | Ajovy |
| Emd Serono, INC. | $1,827.01 | 2019-2025 | Mavenclad |
| Abbvie INC. | $1,595.84 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,087.95 | 2019-2024 | Ongentys, Ingrezza |
| Lundbeck LLC | $684.25 | 2022-2025 | Vyepti |
| Biogen, INC. | $525.49 | 2019-2024 | Vumerity, Plegridy, Avonex |
| Pfizer INC. | $521.61 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $508.32 | 2019-2024 | Zeposia |
| Biohaven Pharmaceutical Holding Company LTD. | $456.09 | 2022 | |
| Novartis Pharmaceuticals Corporation | $435.14 | 2019-2020 | |
| Celgene Corporation | $396.60 | 2021-2025 | Zeposia |
| Amgen INC. | $387.88 | 2019-2024 | Aimovig |
| Genzyme Corporation | $306.23 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $207.86 | 2021 | |
| Avanir Pharmaceuticals, INC. | $201.94 | 2019 | |
| Axsome Therapeutics, INC. | $131.29 | 2025 | Symbravo |
| Acorda Therapeutics, INC | $90.05 | 2019 | |
| Assertio Therapeutics, INC. | $89.56 | 2019 | |
| Ucb, INC. | $60.83 | 2019 | |
| Dexcom, INC. | $42.41 | 2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $37.40 | 2019 | |
| Novo Nordisk INC | $35.51 | 2019-2021 | |
| Boston Scientific Corporation | $35.36 | 2025 | Infinion 16 |
| Genentech USA, INC. | $35.15 | 2019 | |
| Abbott Laboratories | $26.52 | 2019 | |
| Merck Sharp & Dohme LLC | $24.75 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.61 | 2019 | |
| Impel Pharmaceuticals INC. | $23.74 | 2022 | |
| Mdd US Operations, LLC | $22.65 | 2019 | |
| Glaxosmithkline, LLC. | $19.37 | 2021 | |
| Tonix Medicines, INC. | $18.95 | 2025 | Zembrace Symtouch |
| Sanofi Pasteur INC. | $18.33 | 2019 | |
| Adamas Pharmaceuticals, INC. | $14.56 | 2019 | |
| Kyowa Kirin, INC. | $14.52 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.74 | 2019 | |
| Promius Pharma LLC | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Matlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.